研究单位：[1]Vice-Director of Liver Research Center,Beijing Friendship Hospital[2]Beijing Ditan Hospital,Capital Medical University Beijing,Beijing,China,100015[3]Tongji Hospital,Tongji Medical College,Huazhong University of Science ＆Technology Wuhan,Hubei,China,300030[4]The Affiliated Hospital of Yanbian University Yanji,Jilin,China,133000[5]Renji Hospital,Shanghai Jiao Tong University,School of Medicine Shanghai,Shanghai,China,200032[6]Nanfang Hospital,Southern Medical University Guangzhou,Guangdong,China,510515
研究目的：
Patients with chronic hepatitis B histologically confirmed of liver fibrosis S2/S3 (similar to metavir F2/F3, Ishak 2/3/4) are randomly assigned in a 1:1 ratio. One arm is entecavir alone for 2 years; the other is entecavir alone for the first 0.5 year, entecavir plus pegylated interferon (peg-IFN) for 1 year, entecavir for another additional 0.5 year. Patients will be assessed at baseline, at every six months for blood count, liver function test, HBVDNA, AFP, prothrombin time, thyroid function, liver ultrasonography, and Fibroscan. The second liver biopsy will be performed to evaluate regression rate of liver fibrosis 1.5 years after initial therapy.
